Story
Moderna Stock Slides as Investors Reassess Valuation After Cancer Vaccine Rally

Moderna (MRNA) shares fell sharply in morning trading, declining 5.6% to $149.87 as investors took profits following a significant rally last week. The sell-off represents a broader reassessment of the company's valuation after initial enthusiasm for its promising cancer vaccine trial results.
Valuation Concerns Follow Surge
The stock's decline comes after a rally of over 14% on Tuesday, which was fueled by positive analyst actions. However, the primary headwind for the stock is a disconnect between its current market price and Wall Street's fundamental valuations.
Even with recent upgrades, analyst price targets remain well below current trading levels, suggesting concerns that the stock has run up too far, too fast. Key analyst targets include:
- Barclays: Raised its price target to $125.
- Wolfe Research: Upgraded the stock to Peerperform from Underperform.
- JPMorgan: Holds a revised price target of $77.
Fundamental and Market Headwinds
AdUnderlying the valuation debate are Moderna's current financials. The company is not yet profitable, reporting a net loss of $782 million on revenue of just $145 million in its most recent quarter. Analysts note that meaningful revenue from its cancer vaccine, intismeran, is likely still years away due to the complexities of commercialization.
A lack of broad market support is also contributing to the pullback. Major indices like the S&P 500 and Nasdaq were trading flat, providing no tailwind for growth stocks. Furthermore, the wider biotech sector, as measured by the SPDR S&P Biotech ETF (XBI), has also been correcting after surging on the initial news from Moderna and its partner, Merck.
Awaiting the Next Catalyst
Today's decline reflects the natural tension between a significant clinical breakthrough and the long-term commercial realities. The stock's volatile 52-week range, from a low of $22.28 to a high of $176.66, highlights its sensitivity to news flow.
Investors now appear to be reducing exposure while awaiting more concrete developments. The market is looking for the next major catalyst, which would include the presentation of comprehensive efficacy and overall survival data at a medical conference, followed by eventual regulatory submissions.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.